Novartis stock set for holiday-thinned week after FDA breakthrough tag for Sjögren’s drug
Novartis shares rose 0.8% to $144.34 after the company said the FDA granted Breakthrough Therapy designation to ianalumab for Sjögren’s disease. Novartis plans global approval filings in early 2026. U.S. markets will be closed Monday; the company reports earnings Feb. 4.